Idioma:

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Gilbert, Mark R ; Dignam, James J ; Armstrong, Terri S ; Wefel, Jeffrey S ; Blumenthal, Deborah T ; Vogelbaum, Michael A ; Colman, Howard ; Chakravarti, Arnab ; Pugh, Stephanie ; Won, Minhee ; Jeraj, Robert ; Brown, Paul D ; Jaeckle, Kurt A ; Schiff, David ; Stieber, Volker W ; Brachman, David G ; Werner-Wasik, Maria ; Tremont-Lukats, Ivo W ; Sulman, Erik P ; Aldape, Kenneth D ; Curran, Walter J ; Mehta, Minesh P

The New England journal of medicine, 2014-02, Vol.370 (8), p.699-708 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Autor: Gilbert, Mark R ; Dignam, James J ; Armstrong, Terri S ; Wefel, Jeffrey S ; Blumenthal, Deborah T ; Vogelbaum, Michael A ; Colman, Howard ; Chakravarti, Arnab ; Pugh, Stephanie ; Won, Minhee ; Jeraj, Robert ; Brown, Paul D ; Jaeckle, Kurt A ; Schiff, David ; Stieber, Volker W ; Brachman, David G ; Werner-Wasik, Maria ; Tremont-Lukats, Ivo W ; Sulman, Erik P ; Aldape, Kenneth D ; Curran, Walter J ; Mehta, Minesh P
Assuntos: Adult ; Angiogenesis ; Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Bevacizumab ; Biological and medical sciences ; Brain cancer ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Brain Neoplasms - radiotherapy ; Cancer therapies ; Chemotherapy ; Cognition ; Combined Modality Therapy ; Dacarbazine - adverse effects ; Dacarbazine - analogs & derivatives ; Dacarbazine - therapeutic use ; Death ; Disease-Free Survival ; Double-Blind Method ; Drug therapy ; Evidence-based medicine ; General aspects ; Glioblastoma ; Glioblastoma - drug therapy ; Glioblastoma - mortality ; Glioblastoma - radiotherapy ; Glioblastoma multiforme ; Humans ; Immunomodulators ; Immunotherapy ; Intestine ; Ligands ; Medical imaging ; Medical sciences ; Monoclonal antibodies ; Neurology ; Neutropenia ; NMR ; Nuclear magnetic resonance ; Patients ; Pharmacology. Drug treatments ; Proportional Hazards Models ; Quality of life ; Radiation therapy ; Survival ; Survival Analysis ; Targeted cancer therapy ; Temozolomide ; Thromboembolism ; Tumors of the nervous system. Phacomatoses ; Vascular endothelial growth factor
É parte de: The New England journal of medicine, 2014-02, Vol.370 (8), p.699-708
Descrição: The addition of bevacizumab to temozolomide and radiotherapy did not improve overall survival in patients with glioblastoma. Patients receiving bevacizumab had more symptoms, a worse quality of life, and more cognitive impairment than did those receiving placebo. Glioblastoma is the most common primary malignant brain tumor in adults. After maximal surgical tumor resection, the current standard of care is based on a phase 3, randomized clinical trial conducted by the European Organization for Research and Treatment of Cancer and the National Cancer Institute of Canada, which showed that concurrent treatment with daily temozolomide and radiotherapy followed by maintenance temozolomide was superior to radiotherapy alone. 1 , 2 Despite the improvement in outcomes with this combined chemoradiotherapy approach, few patients survive beyond 5 years; therefore, new therapeutic strategies are needed. 3 Angiogenesis is a prominent feature of glioblastoma, most commonly attributed . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.